Global biopharmaceutical market to surpass US$ 167 Billion by 2015

"The Global Biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. Today more than three hundred biopharmaceuticals have already been approved and many more are in late stage clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases, but have also provided the thrust for the continued success of the pharmaceutical industry.

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition and out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry’s US$ 92 billion figures and double digit growth rates in the last five years are a testimonial to the fact that the ones that finally do get approval represent goldmines for investors.

Although factors such as biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, IMARC expects that the high potency and ability of biopharmaceuticals to attack targets beyond the reach of traditional small molecule drugs gives the industry a huge scope for future growth. A rich late stage pipeline and the growth of emerging markets are also expected to be major drivers for growth in the next five years. IMARC expects the global biopharmaceutical market to reach level of sales figures worth more than US$ 167 billion by 2015.

IMARC’s new report “Global Biopharmaceutical Market Report (2010-2015)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2015. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in some form or the other.

Report Highlights
• Biopharmaceuticals enjoy a higher approval success rate compared to traditional small molecule drugs. They, however, require higher investments and take longer development times.

• Biopharmaceuticals are significantly more expensive than traditional medications, with the annual cost of therapy of some biopharmaceuticals touching more than a hundred thousand dollars a year. The cost of these drugs, however, is expected to be closely scrutinized by payers in the coming years.

• Recombinant Proteins represented the biggest biopharmaceutical class in 2009, accounting for more than 65% of the total global biopharmaceutical sales. Growth in this class is expected to be low in most of the developed markets as a result of biosimilar entry and increasing cost containment measures.

• Monoclonal Antibodies are expected to be the biggest drivers of the biopharmaceutical market in the next five years. Driven by a rich late stage pipeline and a strong uptake from both developed and emerging market, Monoclonal Antibodies are expected to be worth more than US$ 79 billion by 2015.

• IMARC expects the top eight markets (US, Germany, Japan, France, Italy, Spain, UK and Canada) to account for around 79% of the total global biopharmaceutical sales by 2015. This represents a decline of 4% over their 2009 share.

• The market share of emerging markets (Brazil, Russia, India, China, Mexico, Turkey and South Korea) is likely to increase from less than 5% in 2009 to more than 8% by 2015.

Regions/Countries Covered
Global, US, Germany, Japan, France, Italy, Spain, United Kingdom, Canada, Russia, China, Australia, Turkey, Mexico, South Korea, India, Brazil, Argentina and Indonesia.

Classes Covered for Each Region/Country
Recombinant Proteins, Insulin, Erythropoietins, Interferons, Colony Stimulating Factors, Immunoglobulins, Recombinant Blood Factors, Growth Hormones, Recombinant Enzymes, Interleukins, Growth Factors, Monoclonal Antibodies and Purified Proteins.

Key Features
• Analysis of the key strengths, weaknesses, opportunities and threats faced by the global biopharmaceutical market.
• Exhaustive in-depth individual analysis for eighteen major developed and emerging markets.
• 2005 to 2009 trend analysis for the global and 18 selected biopharmaceutical markets.
• 2005 to 2009 trend analysis for individual biopharmaceutical classes for the global and 18 selected biopharmaceutical markets.
• 2005 to 2009 trend analysis for the performance of top players for the global and 18 selected biopharmaceutical markets.
• 2010-2015 sales forecast for the global and 18 selected biopharmaceutical markets.

To get the full version of “Global Biopharmaceutical Market Report (2010-2015)” please get in touch with us by emailing us at sales@imarcgroup.com or by calling us on +91-11-43095788

"

"For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
"

IMARC Group
15-a, International Commercial Centre, Mayur Vihar Phase-1 Extension
Delhi-110096
India
contact@imarcgroup.com
91-11-43095788
http://www.imarcgroup.com

This release was published on openPR.